PharmaTelevision - Xceleron: Changing the Face of Clinical Trials

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Xceleron: Changing the Face of Clinical Trials

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

Fintan Walton talks to Professor Colin Garner, founder and CEO of Xceleron, a bioanalytical CRO that is changing the way drugs are developed. Established in 1997 as part of a transatlantic scientific collaboration, the company has taken accelerator mass spectroscopy (AMS) into the drug discovery arena.

Professor Garner talks us through the original aims of the company, its past and present business models and the way it created a market for its services. He touches on the results of the European Union AMS Partnership Programme (EUMAPP) trial and on how AMS technology is radically changing the way in which pharmaceutical companies approach clinical trials and drug selection.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Xceleron's origins.

Fintan Walton:

Hello and welcome to PharmaVentures Business Review here live in San Diego, California. On this show I have Professor Colin Garner, who is CEO of Xceleron which is based both in the UK and the US. Welcome to the show.

Colin Garner:

Thank you.

Fintan Walton:

Colin, Xceleron is a company it has a very specific type of technology which has allowed the company to develop important aspects into the way of drugs are discovered and how drugs can to be dedicated during the clinical phase, could you describe the origins of the company?

Colin Garner:

So the origins of the company, we were founded on academic research which always primarily involved with the University of York who have been academic for far too long. And arouse from collaboration with a group in the United States who had first time used big piece of nuclear physics kit called an accelerator-mass-spectrometry which was originally developed for archaeological dating they had used that for biomedical research and mainly focused on animal research. And in that collaboration with 00.01.31 academic we did some of the first human studies. And that gave us the impetus to think about how this technology could be actually applied in the drug development and drug discovery arena and that was really how we got going.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Richard Seabrook

Chief Executive Officer

Professor Garner's career has spanned both the academic and commercial worlds since he set up the University of York's first spin-out company in 1976. Prior to founding Xceleron in 1997, he founded Biocode Ltd, a monoclonal antibodydiagnostics company and Microtest Research Ltd, a genetic toxicology contract company. He was also the UK's first Professor of Molecular Epidemiology and Director of the Jack Birch Unit for Environmental Carcinogenesis at the University of York. In 1980 he founded the journal of Carcinogenesis and has published over 200 papers and reviews on the environmental causes of cancer. Professor Garnerbecame a Fellow of the Royal College of Pathologists in 1994 and was awarded a DSc in 1995 by the University of London for his scientific contributions to cancer cause and prevention research.

Xceleron

Xceleron is a bioanalytical CRO and spin out company from the Jack Birch Unit for Environmental Carcinogenesis at the University of York. Since 1997, Xceleron has pioneered the application of accelerator-mass-spectrometry (AMS) to biomedical analysis and has highlighted the benefits of human microdosing. First used in 1939, AMS is capable of separating a single molecule of a rare isotope from abundant neighbouring mass, making it 100,000 times more sensitive than mass spectrometry. Its ultra-sensitivity allows human radioactive dosing to be administered on a microdose level, at which regulatory approval for the ionizing radiation is not required. This allows for safer investigation of human ADME/PK, providing more accurate information and allowing trials to be conducted on a wider demographic. Xceleron applies AMS-technology to several key areas of biomedical research: in addition to human microdosing in Phase 0 clinical trials, it is also used in HumanIV-PK,META-ID and Regulatory Mass Balance studies during Phase I trials. Xceleron has bases in the UK and the US and is partnered with over 100 pharmaceutical and biotech companies worldwide.